|
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
|
|
|
Titel: |
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
Auteur: |
Loomba, Rohit Morgan, Erin Yousefi, Keyvan Li, Dan Geary, Richard Bhanot, Sanjay Alkhouri, Naim |
Verschenen in: |
Lancet |
Paginering: |
Jaargang 406 () nr. 10505 pagina's 821-831 |
Jaar: |
2025 |
Inhoud: |
|
Uitgever: |
Elsevier Ltd |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|